1331786-28-7

Basic information

• Product Name: 2-(1-bromoethyl)-1,3-dichloro-4-fluorobenzene
• Synonyms: 2-(1-bromoethyl)-1,3-dichloro-4-fluorobenzene
• CAS NO: 1331786-28-7
• Molecular Weight: 271.944
• Mol File: 1331786-28-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-(1-bromoethyl)-1,3-dichloro-4-fluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-bromoethyl)-1,3-dichloro-4-fluorobenzene(1331786-28-7)
• EPA Substance Registry System: 2-(1-bromoethyl)-1,3-dichloro-4-fluorobenzene(1331786-28-7)

Safety Data

• Hazardous Substances Data: 1331786-28-7(Hazardous Substances Data)

Usage

Benzene derivative

A derivative of benzene This compound is derived from benzene by attaching various functional groups to the benzene ring, which modifies its properties and reactivity.

Bromoethyl group

A C2H4Br group A bromine atom is attached to an ethyl group (two carbon atoms connected by a single bond) in this functional group.

Two chloro groups

Two Cl atoms Two chlorine atoms are attached to the benzene ring, which can influence the compound's reactivity and properties.

Fluorine atom

A single F atom A fluorine atom is attached to the benzene ring, which can affect the compound's electronegativity and reactivity.

Main applications

Pharmaceuticals, agrochemicals, and dyes This compound is primarily used in the production of various pharmaceuticals, agrochemicals (such as pesticides and fertilizers), and dyes for coloring materials.

Organic synthesis intermediate

Can be used as an intermediate in organic synthesis The compound serves as a valuable building block for the synthesis of other organic compounds due to the presence of the bromoethyl, chloro, and fluorine groups.

Hazardous if not properly managed

Handle with caution Due to the presence of halogenated groups, this chemical can be hazardous and should be managed with care to avoid potential risks and adverse effects.

Upstream product

• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 

Downstream Products

• 756503-69-2 (±)-5-bromo-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)pyridin-2-amine 
• 877399-08-1 (±)-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 

Relevant articles and documents

Alkenyl compound and its method and use thereof

The invention provides a new substituted alkenyl compound, pharmaceutically acceptable salts of the new substituted alkenyl compound, a medicinal preparation of the new substituted alkenyl compound, and application of the new substituted alkenyl compound, the pharmaceutically acceptable salts and the medicinal preparation of the new substituted alkenyl compound in aspects of regulating the activity of protein kinase and regulating the intercellular or intracellular signal response. The invention also relates to a medicament composition containing the compound at the same time, and relates to a method for treating high-proliferative diseases of mammals especially the human by using the medicament composition.

SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR

Disclosed are a 2-aminopyridine derivative having protein kinase inhibition activity, a preparation method and a pharmaceutical composition thereof Also disclosed are uses of the compounds and the pharmaceutical compositions thereof in the preparation of drugs for treating and/or preventing protein kinase-related diseases.

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE). Further optimization of the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.